- Home
- CLPR vs TELA Comparison
CLPR vs TELA Comparison
Compare CLPR & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | TELA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 36.7M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLPR | TELA |
|---|---|---|
| Price | $3.17 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 57.3K | ★ 63.8K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.82 | ★ 18.56 |
| 52 Week Low | $3.04 | $0.67 |
| 52 Week High | $4.68 | $2.48 |
Technical Indicators
Market Signals| Indicator | CLPR | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 52.61 |
| Support Level | $3.04 | $0.67 |
| Resistance Level | $3.96 | $0.93 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 30.68 | 81.18 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.